Loading Events

« All Events

  • This event has passed.

An Author Webinar on the Medical Outcome Study-HIV Health Survey (MOS-HIV)

December 1, 2016 @ 10:00 - 11:00 UTC+0

Free
/

Webinar Topic:

An Author Webinar on the Medical Outcome Study-HIV Health Survey (MOS-HIV)

Webinar Date/Time:

Thursday, December 1, 2016 at

10:00 AM - 11:00 AM EST (NYC, USA)

3:00 PM - 4:00 PM GMT (London, UK)

4:00 PM - 5:00 PM CET (Paris, FR)

Webinar Duration:

1 Hour (60 Minutes)

Webinar Host(s):

albert wu author of mos hiv questionnaire

Dr. Albert W. Wu, MD, MPH, FACP - MOS-HIV Questionnaire Author

Albert W. Wu is Professor of Health Policy and Management at the Johns Hopkins Bloomberg School of
Public Health, with joint appointments in Epidemiology, International Health, Medicine, Surgery,
and the Carey Business School. He is director of the Center for Health Services and Outcomes R
search, and of the PhD Program in Health Services Research.

Dr. Wu received his M.D. from the Weill Medical College at Cornell University, and his M.P.H from
the School of Public Health at the University of California-Berkeley.

Dr. Wu is PI or co-investigator on 6 current PCORI funded projects, and co-directs the Research
Facilitating Team for the CMMI funded Johns Hopkins Community Partnership. He teaches a series of
courses at Johns Hopkins on health outcomes, quality of care, comparative effectiveness and patient
safety and has 25 years of experience as a practicing internist and HIV physician at the Johns
Hopkins Hospital. He is currently a member of the National Quality Forum Patient Safety Measures
Permanent committee.

Dr. Wu developed several of the most widely-used patient reported outcome (PRO) measures in HIV,
founded the Outcomes Committee of the NIH AIDS Clinical Trials Group, and led PRO measurement for
the National Eye Institute’s SOCA Research Network. He has used both qualitative and quantitative
research methods in many studies of patient centered outcomes and effectiveness.

Dr. Wu was President of the International Society for Quality of Life Research, and is co-
developer of the PatientViewpoint webtool. He was director the AHRQ-funded Hopkins DEcIDE center
for comparative effectiveness research, which successfully completed 11 task orders on topics
ranging from diabetes medications, to bariatric surgery and chronic kidney disease.

He has conducted research on patient safety since 1988. He was co-PI on a 2001 AHRQ grant to
develop the ICU-Safety Reporting System. He is a core member of the Armstrong Institute for Quality
and Patient Safety, was a member of the IOM Committee on Preventing Medication Errors, and Senior
Adviser in Patient Safety to WHO in Geneva.

Dr. Wu is President of Faculty Senate at Johns Hopkins Bloomberg School of Public Health. He is a
member of the Permanent Patient Safety Committee, National Quality Forum.

Dr. Wu is Associate Editor of the Journal of Patient Safety; Editorial Board: The Patient;
Comparative Effectiveness Research. He recently served on the IOM Committee on Measuring the Impact
of Interprofessional Education on Patient Outcomes.

Dr. Wu has published over 375 peer-reviewed papers with an Impact Factor of 89.

marie d

Marie Dulac - Author Collaboration Unit Coordinator, Mapi Research Trust

Webinar Description:

The MOS-HIV is a brief, comprehensive health status measure containing 35 questions that measure 10 dimensions of health: general health perceptions, pain, physical functioning, role functioning, social functioning, energy/fatigue, mental health, health distress, cognitive function, and quality of life. A single item is also included to assess health transition.

Subscales of the MOS-HIV are scored as summated rating scales on a 0 to 100 scale; higher scores indicate better health. In addition to these subscales, two summary scores can be generated: physical health summary and mental summary scores. The instrument takes approximately five minutes to complete and can be self-administered. Alternatively, it can be given as a face-to-fact or telephone interview.

The MOS-HIV is available in 14 languages and has been included as a secondary outcome measure in numerous clinical trials for all stages of disease. In several studies it has detected significant differences between treatments; in some cases concordant with conventional end-points and, in others, discordant. The interpretation of scores is facilitated by an explanation in terms meaningful to the intended audience.


** Register for this webinar now: **


Email forward this event's registration page to a colleague: